---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007986"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:04:36.788664+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Celularity enters manufacturing collaboration with BlueSphere Bio for AML cell therapy

## Summary
- Master Services Collaboration Agreement to manufacture BlueSphere's TCR T cell therapies for AML.
- Work to be performed at Celularity's 37,000 sq ft Florham Park cGMP facility; dedicated staff and small portion of footprint used.
- BlueSphere's second cell therapy product for AML will be produced; BlueSphere retains oversight.
- Celularity CEO highlights revenue potential of leveraging manufacturing infrastructure for third-party clients.
- BlueSphere expects to dose first patient in TCX-101 program in 1H2025 and file IND for TCX-102 in Q2 2025.

## SEC filing metadata
- accession: 0001493152-25-007986
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315225007986/0001493152-25-007986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315225007986/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007986
- JSON: https://secwatch.observer/filing/0001493152-25-007986.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.